Clinical trial results using fluorescently labeled antibodies (Conference Presentation)

Author(s):  
Eben L. Rosenthal ◽  
Nynke van den Berg ◽  
Tarn Teraphongphom ◽  
Jason Warram
2016 ◽  
Vol 47 (S 01) ◽  
Author(s):  
U. Schara ◽  
C. McDonald ◽  
K. Bushby ◽  
M. Tulinius ◽  
R. Finkel ◽  
...  

Author(s):  
Subha Sankar Paul ◽  
Goutam Biswas

: COVID-19 is a public health emergency of international concern. Although, considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2, till date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir which have shown promising results in different advanced stage of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-Ritonavir combination, although initially was hypothesized to be effective against SARS-CoV-2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action and clinical trial results available in Google and different peer reviewed journals till 24th October 2020.


SAGE Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 215824402110163
Author(s):  
Tariq H. Malik ◽  
Chunhui Huo

Result disclosure of clinical trial posts a conflicting logic between private secrecy and public interest. Despite ethical and legal requirements for disclosing clinical trial results, clinical trials’ sponsors tend to withhold the results. We explored the location, timing, and rationale behind the withheld clinical trial results. Based on the entrepreneurial orientation (EO) perspective, we propose that organizational EO contingencies moderate the disclosure decision. We used the completed clinical trial projects in China by foreign and domestic sponsors. First, we found that a unit increase in the sponsor’s experience can increase the disclosure about 1.01 times. Second, we found that industrial enterprises disclose results about 3.7 times more than universities do. Third, we found that foreign clinical trial projects in China tend to disclose 3.9 times more than domestic projects. We link these findings to two types of audience. First, we inform the academic community on the theory and empirics regarding risk-taking behavior in the biopharmaceutical industry’s clinical trial activity. Second, we address the general audiences concerned about the ethical and socioeconomic wellbeing of the public.


2002 ◽  
Vol 62 (3) ◽  
pp. 1026-1033 ◽  
Author(s):  
Steve J. Schwab ◽  
Mark A. Weiss ◽  
Fred Rushton ◽  
John P. Ross ◽  
Jerry Jackson ◽  
...  

2014 ◽  
Vol 151 (1_suppl) ◽  
pp. P83-P84 ◽  
Author(s):  
Jonathan Kil ◽  
Eric D. Lynch ◽  
Scott Griffiths ◽  
Edward Lobarinas ◽  
Christopher Spankovich ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document